United Therapeutics (UTHR) Long-Term Investments (2009 - 2026)

United Therapeutics has disclosed Long-Term Investments across 18 years of filings, most recently posting $1.3 billion for Q1 2026.

• Long-Term Investments for Q1 2026 came in at $1.3 billion, down 22.99% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.3 billion (down 22.99% YoY), and the FY2025 annual result was $1.8 billion, up 20.43% from the prior year.
• Long-Term Investments came in at $1.3 billion for Q1 2026 at United Therapeutics, down from $1.8 billion in the prior quarter.
• In the past five years, Long-Term Investments ranged from a high of $2.1 billion in Q3 2023 to a low of $1.3 billion in Q3 2024.
• The 5-year median for Long-Term Investments is $1.6 billion (2025), against an average of $1.6 billion.
• Across the five-year window, Long-Term Investments soared 45.1% in 2023 and tumbled 37.92% in 2024, its largest moves.
• United Therapeutics' Long-Term Investments stood at $1.3 billion in 2022, then jumped by 45.1% to $1.9 billion in 2023, then dropped by 22.75% to $1.5 billion in 2024, then increased by 20.43% to $1.8 billion in 2025, then declined by 25.85% to $1.3 billion in 2026.
• The last three Long-Term Investments figures came in at $1.3 billion (Q1 2026), $1.8 billion (Q4 2025), and $1.6 billion (Q3 2025), per Business Quant data.